Table 2.
Participant demographic, laboratory characteristics, and neuroimaging measures at study baseline.
| Characteristic |
Placebo (n = 38) |
Simvastatin (n = 35) |
P Value |
|---|---|---|---|
| Age, mean (SD), y | 55.7 (8.0) | 56.7 (6.3) | 0.57 |
| Female sex, No. (%) | 29 (76.3) | 24 (68.6) | 0.63 |
| White/Caucasian race, No. (%) | 37 (97.4) a | 35 (100) | >0.99 |
| APOE‐ɛ4 positive, No. (%) | 14 (36.8) | 14 (40.0) | 0.97 |
| ASCVD 10‐y risk score, median [IQR] | 2.3 [1.2‐4.8] | 2.8 [1.6‐6.7] | 0.38 |
| BMI, mean (SD) | 28.0 (5.8) | 28.0 (6.0) | 0.98 |
| Blood pressure | |||
| Systolic, mean (SD), mm Hg | 124 (18) | 125 (17) | 0.89 |
| Diastolic, mean (SD), mm Hg | 73 (11) | 73 (11) | 0.73 |
| Antihypertensive medication use, No. (%) | 7 (18.4) | 6 (17.1) | >0.99 |
| Current smoker, No. (%) | 1 (2.6) | 3 (8.6) | 0.55 |
| Alcohol use in last month, No. (%) | 30 (78.9) | 30 (85.7) | 0.65 |
| Serum lipid profile (fasting) | |||
| Total cholesterol, mean (SD), mg/dL | 209 (35) | 205 (37) | 0.56 |
| Triglycerides, mean (SD), mg/dL | 103 (41) | 112 (58) | 0.45 |
| HDL‐C, mean (SD), mg/dL | 64 (17) | 62 (21) | 0.75 |
| LDL‐C, mean (SD), mg/dL | 125 (29) | 120 (30) | 0.45 |
| Neuroimaging measures | |||
| DTI metrics (global white matter) | |||
| Fractional anisotropy (FA), mean (SD) | 0.424 (0.014) | 0.428 (0.013) | 0.15 |
| Mean diffusivity (MD), mean (SD), 10−3 mm3/s | 0.785 (0.024) | 0.784 (0.027) | 0.83 |
| Radial diffusivity (RD), mean (SD), 10−3 mm3/s | 0.591 (0.024) | 0.587 (0027) | 0.54 |
| Axial diffusivity (AD), mean (SD), 10−3 mm3/s | 1.175 (0.028) | 1.178 (0.030) | 0.61 |
| Total GM volume, mean (SD), mL | 627 (56) | 633 (58) | 0.67 |
| Total WM volume, mean (SD), mL | 508 (60) | 508 (61) | 0.98 |
| Total intracranial volume (TIV), mean (SD), mL | 1436 (134) | 1446 (130) | 0.75 |
| Total WMH lesion volume, median [IQR], mL | 0.72 [0.19‐1.47] | 0.45 [0.17‐1.69] | 0.81 |
Abbreviations: APOE, apolipoprotein E; ASCVD, atherosclerotic cardiovascular disease; BMI, body mass index; DTI, diffusion tensor imaging; GM, gray matter; HDL‐C, high‐density lipoprotein cholesterol; LDL‐C, low‐density lipoprotein cholesterol; WM, white matter; WMH, whitematter hyperintensity.
a
One American Indian/Native American participant in placebo group.